Teva Pharmaceutical Industries Limited (NYSE:TEVA) has seen a significant increase of its shares held by institutional investors. A key win has boosted the turnaround story of the company and Teva’s stock rose 72.5% this year. Surprisingly,
Daiwa Securities Group Inc. sold a notable amount of its Teva shares while Commonwealth Equity Services LLC also decreased their holdings in the company. Despite this, the company's shares soared 27%, largely due to its promising schizophrenia treatment. Q1 results, although missing profit estimates, revealed unusual call option activity.
Teva Pharmaceutical has further seen stock price increases after Q2 earnings were reported. One notable milestone was an upgrade from Piper Sandler, along with anticipation of positive outcomes from the duvakitug trials. Despite successful Q1 earnings, the company's EVP, CFO Eliyahu Kalif sold a significant amount of shares, however, private Management Group Inc. and Victory Capital Management Inc. have large positions in Teva. Despite some concerns about Teva's business, the company has stated that the potential of the company outweighs these concerns. The company is also due to divest its active pharmaceutical ingredient business. Ultimately, the company’s ‘Pivot to Growth’ strategy earned them a positive rating.
Teva Pharmaceutical Stocks News Analytics from Wed, 04 Oct 2023 07:00:00 GMT to Sun, 15 Sep 2024 12:35:49 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor -2
